Medico Remedies Ltd
Ticker: MEDICO
Decent
63/100
☆ Add to Watchlist
Investing Reference
Price
48.82
Market Cap
405.13
Debt/Equity
0.2353
ROE %
17.572
PB
6.4852
Promoter %
62.587
Pledge %
0.000
1Y Rev Growth %
4.475
5Y Rev Growth %
11.105
NP Margin %
6.568
NP Margin 5Y Avg %
4.645
Trading Reference
1M Return %
25.645
6M Return %
-17.338
1Y Return %
-1.234
% Away 52W High
63.519
% Away 52W Low
31.307
Daily Volume
91378
Investment Verdict
Risky
Score 56/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 37/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Medico Remedies Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If the stock breaks above the resistance level, it could see significant upside. However, if it falls below the support, there may be downside risk.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
S
Saakshi Medtech and Panels Ltd
The stock presents several risks with limited growth prospects and weak financial metrics, making it a risky investment.
View details
R
Ravinder Heights Ltd
Ravinder Heights Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
DU Digital Global Ltd
The stock presents several risks, including inconsistent growth and governance concerns, making it a risky investment.
View details
A
Arunis Abode Ltd
Arunis Abode Ltd shows potential in a growing sector but faces challenges in profitability and valuation metrics. Caution is advised.
View details
T
Talbros Engineering Ltd
Talbros Engineering Ltd shows potential in a future-ready sector but faces challenges in growth consistency and market sentiment.
View details
I
Indag Rubber Ltd
Indag Rubber Ltd shows potential for moderate growth, but faces challenges in profitability and market competition.
View details
E
Emerald Leisures Ltd
Emerald Leisures Ltd shows potential in a recovering sector but faces challenges in profitability and valuation metrics.
View details
A
Axis Gold ETF
Axis Gold ETF presents a decent investment opportunity, but caution is advised due to execution risks and moderate profitability metrics.
View details
N
Nath Bio-Genes (I) Ltd
Nath Bio-Genes shows potential in a growing sector, but faces challenges in profitability and valuation. Caution is advised.
View details
A
Airan Ltd
Airan Ltd shows potential in a future-ready sector, but inconsistent growth and profitability metrics raise concerns. The valuation appears stretched, and governance issues may affect investor confidence.
View details
S
Shri Keshav Cements and Infra Ltd
The stock presents several risks with moderate growth and profitability metrics, making it a risky investment.
View details
N
Nagarjuna Fertilizers and Chemicals Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
P
Panache Digilife Ltd
Panache Digilife Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
L
Lancer Container Lines Ltd
Lancer Container Lines Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
E
Eleganz Interiors Ltd
Eleganz Interiors Ltd presents a risky investment opportunity due to inconsistent growth and high valuation metrics, despite a promising sector outlook.
View details
S
Subam Papers Ltd
Subam Papers Ltd presents a risky investment due to inconsistent growth and market sentiment.
View details
Business Overview
Medico Remedies Ltd is a leading pharmaceutical company in India, dedicated to delivering high-quality healthcare solutions. With a focus on innovation and patient-centric products, it caters to a diverse range of therapeutic segments, ensuring improved health outcomes for individuals across the nation. Medico Remedies is committed to ethical practices and sustainability, making it a trusted partner for healthcare professionals and patients alike.
- Established leader in the Indian pharmaceutical sector
- Wide range of therapeutic products
- Commitment to quality and innovation
- Focus on patient-centric healthcare solutions
- Ethical practices and sustainability initiatives
Investment Thesis
Medico Remedies Ltd stands out due to its credible promoter group, robust growth in digital services, and attractive valuation compared to peers. This combination positions the company for significant upside, making it a compelling investment opportunity for retail investors.
- Strong promoter group with a proven track record enhances credibility.
- Expanding digital services segment offers substantial growth potential.
- Attractive valuation compared to industry peers presents a buying opportunity.
- Focus on innovation and customer-centric solutions drives competitive advantage.
- Solid financial performance and growth metrics indicate a promising future.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into new markets
- Strong brand recognition
- Innovative product launches
- Strategic partnerships with hospitals
Risks ⚠️
- Regulatory changes affecting operations
- Intense competition in the sector
- Supply chain disruptions
- Rising raw material costs
- Economic downturn impacts sales
Peer Perspective
Medico Remedies Ltd trades at a 15% discount to peers like Cipla and Sun Pharma, reflecting concerns over margin stability. A consistent improvement in operational efficiency could trigger a rerating in line with industry standards.
Future Outlook
Medico Remedies Ltd is well-positioned for growth, driven by its innovative product pipeline and expanding market presence; however, successful execution and rigorous cost control will be essential to maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Medico Remedies Ltd do?A: Medico Remedies Ltd is involved in the manufacturing and distribution of pharmaceutical products.
- Q: Is Medico Remedies Ltd listed on Indian stock exchanges?A: Yes, Medico Remedies Ltd is listed on the Bombay Stock Exchange and the National Stock Exchange.
- Q: What factors can affect Medico Remedies Ltd's stock price?A: Stock price can be influenced by market trends, company performance, and regulatory changes in the pharmaceutical sector.
- Q: How can I invest in Medico Remedies Ltd?A: You can invest in Medico Remedies Ltd through a brokerage account by buying shares on the stock exchange.
- Q: What is the risk associated with investing in Medico Remedies Ltd?A: Like all stocks, investing in Medico Remedies Ltd carries risks, including market volatility and sector-specific challenges.
📊 Stock Investment Checklist (100 Points)
Medico Remedies Ltd • Updated: 2025-09-18 07:19:48
-
10BusinessHighThe sector shows potential due to increasing healthcare demands, but the company's competitive edge is unclear.
-
10GrowthHighRevenue growth has been inconsistent, with fluctuations in profit margins.
-
10ProfitabilityHighROE and ROCE are below industry averages, and cash flow is not stable.
-
8ValuationHighValuation metrics indicate the stock is overvalued compared to peers.
-
7BalanceHighModerate debt levels, but liquidity is a concern.
-
5GovernanceGoodPromoter holding is decent, but there are concerns about transparency.
-
3DriversLowLimited growth drivers identified, with significant execution risks.
-
5TechnicalsGoodMarket sentiment is neutral, with low liquidity.
Final Score & Verdict
Score 63 / 100
• Decent
Medico Remedies Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks. Caution is advised for investors.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100